Kantor Boris, McCown Thomas, Leone Paola, Gray Steven J
Department of Pharmacology, Physiology, and Neuroscience, University of South Carolina, Columbia, SC, USA.
Gene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Adv Genet. 2014;87:71-124. doi: 10.1016/B978-0-12-800149-3.00002-0.
Diseases of the central nervous system (CNS) have traditionally been the most difficult to treat by traditional pharmacological methods, due mostly to the blood-brain barrier and the difficulties associated with repeated drug administration targeting the CNS. Viral vector gene transfer represents a way to permanently provide a therapeutic protein within the nervous system after a single administration, whether this be a gene replacement strategy for an inherited disorder or a disease-modifying protein for a disease such as Parkinson's. Gene therapy approaches for CNS disorders has evolved considerably over the last two decades. Although a breakthrough treatment has remained elusive, current strategies are now considerably safer and potentially much more effective. This chapter will explore the past, current, and future status of CNS gene therapy, focusing on clinical trials utilizing adeno-associated virus and lentiviral vectors.
中枢神经系统(CNS)疾病传统上是最难用传统药理学方法治疗的,这主要是由于血脑屏障以及针对中枢神经系统重复给药所带来的困难。病毒载体基因转移代表了一种在单次给药后就能在神经系统中永久提供治疗性蛋白质的方法,无论是针对遗传性疾病的基因替代策略,还是针对帕金森氏症等疾病的疾病修饰蛋白。在过去二十年中,针对中枢神经系统疾病的基因治疗方法有了很大的发展。尽管突破性的治疗方法仍未出现,但目前的策略现在要安全得多,而且可能更有效。本章将探讨中枢神经系统基因治疗的过去、现状和未来状况,重点关注利用腺相关病毒和慢病毒载体的临床试验。